Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul-Aug;76(4):268-270.
doi: 10.1016/j.ihj.2024.07.003. Epub 2024 Jul 14.

Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

Heemanshu Lodhi  1 , Keshavamurthy Ganapathy Bhat  2 , Vivek Singh Guleria  2 , Ratheesh Kumar Janardhana Pillai  2 , Ribhu Goel  2 , Nitin Sharma  2 , Anuka Sharma  3 , Varun Sharma  3
Affiliations

Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

Heemanshu Lodhi et al. Indian Heart J. 2024 Jul-Aug.

Abstract

Aim: The genetic polymorphism of CYP2C19 influences clopidogrel metabolism and resistance. Aim was to assess the association between CYP2C19 loss of function variation, clopidogrel resistance based on platelet reactivity units and clinical outcomes.

Methods: A total of 668 patients of Acute Coronary Sundrome (ACS) who underwent Percutaneous Coronary Intervention (PCI) were subjected to genetic screening and 143 patients undrewent platelet function test to study the association between drug metabolization and its effects based on platelet reactivity unit values.

Results: Clopidogrel resistance with CYP2C 19 loss of function variation was noted in 54.64% of patients. Clinical outcomes, such as target vessel revascularization, target lesion revascularization, in-stent restenosis, and stent thrombosis, were also studied.

Conclusion: CYP2C19 loss of function variation is strongly associated with clopidogrel resistance and adverse clinical outcomes.

Keywords: Acute coronary syndrome; CYP2C19; Clopidogrel resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors declare no competing interest. Dr. Anuka Sharma and Dr. Varun Sharma are the employees of NMC Genetics India Private Limited.

Figures

Fig. 1
Fig. 1
Impact of CYP2C19 variants on enzyme activity and clopidogrel metabolism. Figure illustrates the impact of CYP2C19 genetic variants on enzyme activity and clopidogrel metabolism. The image depicts four metabolizer phenotypes: Normal (Ultra and extensive metaboliser * 1/17,*17/*17, *1/*1), Intermediate (*1/*2 or *1/*3), and Poor (*2/*2, *2/*3, or *3/*3). Enzyme activity progressively decreases from normal to poor metabolizers, represented by a color gradient from green to red. The figure demonstrates the conversion efficiency of clopidogrel to its active metabolite for each phenotype. Normal metabolizers exhibit efficient conversion and platelet inhibition, while poor metabolizers show minimal conversion and inadequate inhibition. This visual representation effectively explains why individuals with certain CYP2C19 variants may experience reduced clopidogrel efficacy, potentially increasing their risk of adverse cardiovascular events in acute coronary syndrome patients undergoing percutaneous coronary intervention.
See this image and copyright information in PMC

References

    1. Brown S.A., Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Personalized Med. 2018;8 - PMC - PubMed
    1. Karazniewicz-Lada M., Danielak D., Glowka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expet Opin Pharmacother. 2012;13:663–683. - PubMed
    1. Ray S. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66:530–534. - PMC - PubMed
    1. El Abdallaoui O.E.A., Tornyos D., Lukacs R., Szabo D., Komocsi A. Individualized or uniform de-escalation strategies for antiplatelet therapy in acute coronary syndrome: a Review of clinical trials with platelet function testing and genetic testing-based protocols. Int J Mol Sci. 2023;24 - PMC - PubMed
    1. Bhat K.G., Pillai R.K.J., Lodhi H., et al. Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians. J Gene Med. 2024;26:e3634. - PubMed